Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
Emerging Therapies, Including Bristol-Myers Squibb/Medarex's Ipilimumab, Will Drive Growth in the Malignant Melanoma Drug Market
October 1st, 2008
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the malignant melanoma drug market, driven by the launch of emerging agents, will experience robust annual 12 percent growth through 2012 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. Thereafter, the market will grow by six percent annually through 2017. The new Pharmacor report entitled Malignant Melanoma finds that the launch of Bristol-Myers Squibb/Medarex's ipilimumab, first in the metastatic setting and later in the adjuvant setting, will significantly increase the size of the malignant melanoma drug...
Source: Vaccine Weekly (2008-10-01)
|
